Clinical Research Directory

Inclusion Criteria: * After full informed consent, voluntarily participate in this study and sign the written Informed Consent Form (ICF), and agree to abide by the procedures specified in the study protocol; * No pregnancy, sperm donation or egg donation plan from the start of screening to 30 days after the last administration of investigational product, and agree to completely abstain from sexual activity or adopt effective contraceptive measures throughout the period from screening to 30 days after the last administration of investigational product; * Male or female trial participants aged 18 to 45 years old (inclusive of 18 and 45 years old); * Male trial participants weigh no less than 50 kg, female trial participants weigh no less than 45 kg. Body Mass Index (BMI) = weight (kg) / height² (m²), and the Body Mass Index is within the range of 19 \~ 26 kg/m² (inclusive of the critical values); * Vital signs, physical examination, laboratory tests, electrocardiogram, abdominal color ultrasound (liver, gallbladder, spleen, pancreas, bilateral kidneys) and chest X-ray (anteroposterior view) results are normal, or abnormal findings are judged by the investigator to be clinically insignificant. Exclusion Criteria: * History of herpes zoster or severe herpes simplex, or presence of herpes zoster/herpes simplex during the screening period; * Individuals who cannot tolerate venipuncture/indwelling needle blood collection, or have needle phobia and hemophobia; * Previously received surgeries that may affect drug absorption, distribution, metabolism and excretion, and are judged by the investigator to be unsuitable for enrollment; * Individuals with a history of drug or substance abuse, or with a positive urine drug abuse screening result; * Trial participants who have other factors that the investigator considers inappropriate to participate in this trial.